Sri Lanka Successfully Lowers Seasonal Flu Impact with Antiviral Use
Sri Lanka Enhances Influenza Preparedness with Targeted Testing and Treatment
Strengthening Influenza Response in Sri Lanka
Sri Lanka is bolstering its influenza response through a multipronged strategy emphasizing rapid testing, timely treatment, and the integration of maternal health. Supported by the World Health Organization (WHO), the nation is working to improve preparedness for future pandemics by building an evidence base on the impact of influenza and the benefits of vaccination.
Focus on Rapid Testing and Treatment
To mitigate hospitalizations and fatalities caused by seasonal influenza, Sri Lanka is prioritizing rapid testing and treatment. National clinical guidelines now advocate for the use of oseltamivir among high-risk groups to prevent severe illness and reduce infection duration. This proactive approach not only saves lives but also supports local pharmaceutical production, ensuring a steady supply of antivirals for seasonal outbreaks and potential future pandemics.
Integrating Influenza Care with Maternal Health
A crucial component of Sri Lanka’s strategy is integrating influenza care within Reproductive, Maternal, Newborn, Child, and Adolescent Health (RMNCH+A) services, particularly focusing on pregnant women. Following a period in 2015 and 2016, where influenza contributed to 10% of maternal deaths, the Ministry of Health took swift action. Pregnant women presenting with fever and respiratory symptoms are now encouraged to seek immediate medical attention, with oseltamivir treatment recommended within 24–48 hours of symptom onset when necessary.
Extensive health education campaigns and training at antenatal clinics help ensure women are aware of influenza symptoms and seek timely care, effectively reducing maternal mortality related to influenza.
Collaboration with WHO for Future Preparedness
In July 2025, representatives from WHO, including the South-East Asia Regional Office and the Sri Lanka Country Office, met with national health leaders such as the Director-General of Health Services, Dr. Asela Gunawardena, and Chief Epidemiologist, Dr. Hasitha Tissera. These discussions aimed to advance Sri Lanka’s antiviral strategy by incorporating influenza vaccines into a comprehensive prevention and control program.
Research and Future Plans for Vaccination
Looking ahead to 2025–2026, the Ministry of Health plans to conduct analyses on the burden of influenza, assessing the potential reductions in hospitalizations, deaths, and absenteeism achievable through vaccination. These studies will complement research from the University of Ruhuna and Duke University, which highlights the cost-effectiveness of introducing influenza vaccines in Sri Lanka. WHO is also assisting in updating the national immunization handbook to include influenza vaccination guidance, fostering effective vaccine utilization.
By blending rapid antiviral treatment, local pharmaceutical production, and evidence-based vaccine policy, Sri Lanka is taking significant steps to protect vulnerable populations and enhance its preparedness for future pandemics.
